Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · IEX Real-Time Price · USD
2.710
-0.060 (-2.17%)
At close: Apr 18, 2024, 4:00 PM
2.680
-0.030 (-1.11%)
After-hours: Apr 18, 2024, 7:46 PM EDT
Heron Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Heron Therapeutics stock has a target of 5.00, which predicts an increase of 84.50% from the current stock price of 2.71.
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for HRTX is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +84.50% | Apr 11, 2024 |
| Needham | Needham | Strong Buy Maintains $4 → $5 | Strong Buy | Maintains | $4 → $5 | +84.50% | Mar 13, 2024 |
| Needham | Needham | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +47.60% | Nov 15, 2023 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +84.50% | Aug 15, 2023 |
| Needham | Needham | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +84.50% | Jul 25, 2023 |
Financial Forecast
Revenue This Year
148.85M
from 127.04M
Increased by 17.16%
Revenue Next Year
179.01M
from 148.85M
Increased by 20.26%
EPS This Year
-0.46
from -0.80
EPS Next Year
-0.37
from -0.46
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 158.9M | 189.3M | 232.8M | 283.6M | 386.3M |
| Avg | 148.9M | 179.0M | 219.0M | 270.1M | 329.1M |
| Low | 135.2M | 167.8M | 203.6M | 249.3M | 286.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 25.1% | 27.2% | 30.0% | 29.5% | 43.0% |
| Avg | 17.2% | 20.3% | 22.3% | 23.3% | 21.8% |
| Low | 6.5% | 12.7% | 13.7% | 13.8% | 6.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.21 | -0.02 | 0.26 | 0.51 | 1.00 |
| Avg | -0.46 | -0.37 | 0.12 | 0.39 | 0.61 |
| Low | -0.77 | -0.89 | - | 0.27 | 0.35 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 311.8% | 157.4% |
| Avg | - | - | - | 210.2% | 56.1% |
| Low | - | - | - | 119.6% | -9.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.